Periodical dosing of vitamin B12 should be performed in the case of patients with Type 2 Diabetes Mellitus treated with metformin, especially if they associate anemia and/or peripheral diabetic polyneuropathy (Diabetes, Metabolic Syndrome and Obesity)
Diabetes News
Category: Medication
SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes
Treatment with SGLT2 inhibitors results in clear and consistent reductions in cardiovascular, kidney and mortality outcomes regardless of whether patients are receiving or not receiving metformin (Diabetes, Obesity and Metabolism)
Metformin use in prediabetes: is earlier intervention better?
The largest reductions in both incidence of diabetes and FPG occurred in prediabetic persons with a higher level of FPG at baseline. Metformin was able to stabilise insulin sensitivity and was more effective in persons with more pronounced IFG (Acta Diabetologica)
Effects of SGL2 inhibitors on liver parameters and steatosis: a meta‐analysis of randomized clinical trials
Treatment with SGLT2 inhibitors improves liver structure and function in patients with type 2 diabetes. This meta‐analysis suggests that SGLT2 inhibitors are a promising pharmacological approach to NAFLD (Diabetes/Metabolism Research and Reviews)
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19
In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment (Diabetes Care)
Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial
Eighteen months of metformin treatment in combination with insulin compared with insulin alone increased early drop in OBP indicating an adverse effect of metformin on CAN independent of vitamin B12, MMA HbA1c (Cardiovascular Diabetology)
Dapagliflozin in Patients with Chronic Kidney Disease
Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo (NEJM)
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes (NEJM)
Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes
This review summarizes pharmacogenomic evidence of some current antidiabetic agents applied in clinical settings, and highlights potential drugs with new targets for diabetes, which represent a more effective treatment in the future (Diabetes Therapy)
Potential Unrealized Mortality Benefit of GLP‐1 Receptor Agonists and SGLT2 Inhibitors
This analysis indicates unrealized opportunities to reduce mortality in selected Veterans with T2D and CAD via increased use of GLP‐1RA and SGLT2i (Diabetes, Obesity and Metabolism)
Lower Cardiorenal Risk with Sodium‐Glucose Cotransporter‐2 Inhibitors versus Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases
In this multinational observational study, SGLT2i was associated with lower risk of heart failure and chronic kidney disease versus DPP4i in T2D patients otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)
Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes
Overall, the improved postprandial blood glucose levels and increase in incretins observed in the absence of changes in insulin sensitivity and gluconeogenesis, support an enteroinsular mechanistic pathway in youth with type 2 diabetes treated with short-term metformin (Diabetologia)
Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
Based on the current understandings and lessons learned from the most recent studies, we discussed the importance of future research on the safety and efficacy of SGLT2 inhibitor in clinical situations of HF other than those examined in previous cardiovascular outcome trials (Cardiovascular Diabetology)
Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis
These data indicate that SGLT-2is is more beneficial to MACE and all-cause mortality in T2DM patients than DPP-4is (Primary Care Diabetes)
Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis
The clinical effectiveness of liraglutide is maintained long term (up to 5 years). Liraglutide treatment is not associated with higher total direct healthcare costs (Diabetes Therapy)
Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis
The addition of DPP4i to insulin is associated with a statistically significant reduction in glycemic control as measured by HbA1c, fasting plasma glucose, and 2-h postprandial glucose, without increasing the risk of hypoglycemia and weight gain. These conclusions were also observed in both stable-dose and flexible-dose insulin subgroups (Diabetes Therapy)
Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis
This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy (Journal of Clinical Endocrinology & Metabolism)
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
In clinical trials, oral semaglutide 14 mg reduced mean HbA1c by approximately 1.1–1.5% and reduced body weight by up to 5 kg. The most common side effects were gastrointestinal, mainly mild-to-moderate and transient nausea. Oral semaglutide may offer a practical and effective means of managing people living with T2D who require treatment intensification, and may change the paradigm of care in the primary care setting (Primary Care Diabetes)
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
Metformin use is associated with early risk of anemia in individuals with type 2 diabetes, a finding consistent across two RCTs and replicated in one real-world study (Diabetes Care)
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability (Diabetes Therapy)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 42
- Next Page »
Glycosmedia is also available as an App: